Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5515263 | 0.81 | HMGCR (0.37) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL28291059 | 0.81 | HMGCR (0.37) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL27507342 | 0.78 | HMGCR (0.39) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL24362107 | 0.78 | HMGCR (0.39) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL28602466 | 0.78 | TDP1 (0.39) | TSHRALDH1A1FFAR1CPT2TDP1 | |
| SCHEMBL29020317 | 0.78 | HMGCR (0.34) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL25662697 | 0.76 | ALDH1A1 (0.47) | TSHRFFAR3ALDH1A1FFAR1TDP1 | |
| SCHEMBL6338152 | 0.73 | HMGCR (0.44) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL28713981 | 0.73 | HMGCR (0.50) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL10554689 | 0.73 | HMGCR (0.34) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320174-A1 | SPIN ON METAL-ORGANIC FORMULATIONS | MERCK PATENTS GMBH (DE) | 2025-10-16 | — | — | US | claimed |
| EP-4334252-A2 | SPIN ON METAL-ORGANIC FORMULATIONS | Merck Patent GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| CN-117295693-A | Spin-on metal-organic formulations | 默克专利股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| WO-2022233919-A2 | SPIN ON METAL-ORGANIC FORMULATIONS | MERCK PATENT GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| EP-4641061-A1 | OIL-WELL METAL PIPE | NIPPON STEEL CORPORATION (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-20250320174-A1 | SPIN ON METAL-ORGANIC FORMULATIONS | MERCK PATENTS GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| WO-2024135464-A1 | OIL-WELL METAL PIPE | 日本製鉄株式会社 | 2024-06-27 | — | — | WO | disclosed |
| EP-4334252-A2 | SPIN ON METAL-ORGANIC FORMULATIONS | Merck Patent GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| CN-117295693-A | Spin-on metal-organic formulations | 默克专利股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2022233919-A2 | SPIN ON METAL-ORGANIC FORMULATIONS | MERCK PATENT GMBH (DE) | 2022-11-10 | — | — | WO | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | HMGCR 3266/4885CHRM1 36/4885TBXA2R 288/4885 |
| US-20250320174-A1 | SPIN ON METAL-ORGANIC FORMULATIONS | SLC39A11, SLC39A3, SLC39A7 | HMGCR 1686/4885CHRM1 776/4885TBXA2R 3307/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | HMGCR 2709/4885CHRM1 12/4885TBXA2R 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.